PTJ
INDV icon

Paul Tudor Jones’s Indivior Pharmaceuticals INDV Stock Holding History

Paul Tudor Jones’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-45,478
Closed -$565K – 3322
2024
Q4 		$565K Buy
45,478
+24,137
+113% +$248K ﹤0.01% 2144
2024
Q3 		$208K Buy
21,341
+1,341
+7% +$15.7K ﹤0.01% 2519
2024
Q2 		$322K Buy
+20,000
New +$361K ﹤0.01% 1987

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Paul Tudor Jones's INDV Position: Q1 2025 in Review

Paul Tudor Jones sold out of Indivior Pharmaceuticals (INDV) in Q1 2025, closing a stake of 45,478 shares — an estimated $565K sold.

Paul Tudor Jones first reported a position in INDV in Q2 2024 and held it in 3 quarters. The position peaked at $565K in Q4 2024. 116 funds tracked by Wall St. Rank hold INDV as of Q1 2025.

  • Paul Tudor Jones reported no remaining Indivior Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 45,478 Indivior Pharmaceuticals shares in Q1 2025, an estimated $565K.
  • Paul Tudor Jones first reported a position in Indivior Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Paul Tudor Jones's Indivior Pharmaceuticals position peaked at $565K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2025.

Based on Tudor Investment Corp's 13F filing for Q1 2025, filed 15 May 2025.